Quantum Cyber (QUCY) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Nov, 2026Executive summary
Q3 continuing-operations revenue was $966,833, generated by the acquired Bridgeport precision metal-stamping and fabrication business; no drone sales had begun by September 30.
Q3 net loss widened to $5.38 million from $2.92 million YoY amid higher operating expenses and investment in the drone strategy.
Financial highlights
Q3 revenue was $966,833, cost of revenue $873,243 and gross profit $93,590; continuing-operations revenue was nil in Q1 and Q2 2026 and prior-year periods.
Q3 operating expenses were $4.96 million and operating loss was $4.86 million, versus $1.17 million for each measure YoY.
Nine-month revenue was $966,833, gross profit $93,590 and operating expenses $17.51 million, including $4.26 million of acquired IPR&D expense; reported nine-month operating loss was $17.41 million.
Nine-month net loss was $21.48 million versus $11.40 million YoY; Q3 basic and diluted loss per share was $0.08 versus $0.42, and nine-month loss per share was $0.69.
Outlook and guidance
Drone manufacturing and sales at Bridgeport are targeted to begin in early 2027, subject to facility build-out, equipment procurement, production-line development, prototype completion and market acceptance; no purchase orders had been received.
An 80-unit 3D-printing production farm was installed in August 2026 as Bridgeport continued operating its stamping business and being prepared for drone manufacturing.
The CEO committed up to $8.0 million through November 30, 2027, as equity, debt or a combination; terms remain subject to agreement and no funding had been drawn by issuance.
Latest events from Quantum Cyber
- Shifted to quantum drones, posted $16.1M loss, raised $21M, and faces execution risks.QUCY
H1 2026 - Plans to raise $250M for AI and quantum-driven autonomous vehicle platforms via multi-type securities.QUCY
Registration filing - Annual meeting to vote on key proposals, board changes, and expansion into quantum cybersecurity.QUCY
Proxy filing - Annual meeting to vote on key proposals, board changes, and expanded authorizations.QUCY
Proxy filing - Strategic pivot, asset sales, and capital raises mark Q1 2026 amid ongoing losses and cash improvement.QUCY
Q1 2026 - 2025 saw a strategic pivot to pancreatic cancer diagnostics, a 40% revenue drop, and a $16.2M net loss.QUCY
H2 2025 - Approval of all proposals enables a $6M investment, board overhaul, and recapitalization.QUCY
Proxy filing - Shareholders will vote on a $6M investment, board overhaul, and major capital structure changes.QUCY
Proxy Filing - Offering up to $150M in securities to advance innovative cancer diagnostics amid high risk.QUCY
Registration Filing